Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.0% during the 4th quarter, HoldingsChannel reports. The fund owned 4,030,634 shares of the biotechnology company’s stock after purchasing an additional 228,457 shares during the period. Ascendis Pharma A/S accounts for approximately 3.0% of Westfield Capital Management Co. LP’s portfolio, making the stock its 2nd biggest holding. Westfield Capital Management Co. LP owned 0.07% of Ascendis Pharma A/S worth $507,658,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in Ascendis Pharma A/S during the fourth quarter valued at $25,000. Quadrant Capital Group LLC grew its stake in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares during the last quarter. Signaturefd LLC raised its position in Ascendis Pharma A/S by 31.9% during the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 193 shares in the last quarter. Finally, Legato Capital Management LLC acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $204,000.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND traded up $0.97 during trading hours on Friday, hitting $130.41. 250,225 shares of the company’s stock were exchanged, compared to its average volume of 396,952. The company’s 50-day moving average price is $140.23 and its 200-day moving average price is $131.61. Ascendis Pharma A/S has a 1-year low of $83.75 and a 1-year high of $161.00. The stock has a market capitalization of $7.59 billion, a price-to-earnings ratio of -13.57 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The business had revenue of $103.11 million for the quarter, compared to analyst estimates of $85.72 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. On average, research analysts expect that Ascendis Pharma A/S will post -5.03 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Morgan Stanley boosted their price target on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Finally, Wedbush boosted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $176.88.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.